Excited to see our paper in print @EUplatinum: https://t.co/9G6F1Q2Q5y Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma

On the anniversary of his passing, remember Felix's love, brilliance, humor, and determination to cure cancer. Please consider donating to this American Cancer Society-ASTRO fund, to support promising clinician scientists in their fight against cancer.

A year ago today we lost @felixfengmd and I think of him every day. We know you’re up there cracking a joke, dreaming up the next big paper or or grant or company, having a milk tea, or about to call us at an inopportune time about something actually quite important.

Our 2025 Urology Year in Review is here! Our momentum is built on the dedication of our faculty, learners, alumni and partners. Thank you for everything you do https://t.co/2KWsIV3mUT

Dr. Samson Fine takes us through the finer points of GS4 prostate cancer at #SUO2025. Quantification and subtype are important, large cribriform present in patients with metastases after prostatectomy @rovingatuscap @MSKCancerCenter

Standing ovation for @pcarroll_ recipient of this year’s Huggins medal #SUO2025. Astounding vision, intellect, and impact on the field and our patients. Congratulations. #SUO2025 @UCSFUrology @UCSFCancer

So proud of my co fellows and all they are doing but mostly just glad to have my brothers and forever tumor board in person at #SUO2025 @UroOnc @MSKCancerCenter @UrologyMSK

Robotic (SP) ILND for cN0 penile cancer - appealing for reducing complications but limited prospective data. Balanced talk by @ccp1983 @UABUrology with an import disclosure “I don’t worship the robot” #SUO2025

Please join us for our upcoming Grand Rounds with a presentation by Dr. Bogdana Schmidt! @BogdanaSchmidt @huntsmancancer 🗓️ Wednesday, December 10, 2025 ⏰ 6:30 am- 7:30 am PST 💻 Register for Zoom webinar: https://t.co/9r7gWAx1g8

Love attending @UroOnc Annual Meeting, but especially when @UrologyMSK ‘21-23 can make it too @sari_safaa @BenBeechMD @SongJiangUro @CChuMD (missing @drMPerera and Alex Doudt)

The FDA approval of EV + Pembro in cisplatin ineligible muscle invasive bladder is based on pCR=57% & OS HR of 0.5 vs cystectomy alone. Initial systemic therapy rather than surgery is now preferable for all eligible pts. I suspect this is not the last we hear from EVP in MIBC.

At #uromigosLive a mock ODAC (UDAC) took place for ICI therapy +BCG in NMIBC. The votes for both favoured approval 7-1 for durvalumab (POTOMAC trial @DrRosenbergMSK ) 5-4 for salanlimab (CREST trial @tompowles1). See video 👉 https://t.co/Jyo228wYQy . This is in contrast to the

🚨Our new paper is out today in Nature! We show that SARS-CoV-2 mRNA vaccines can sensitize tumors to immune checkpoint blockade (ICI) — revealing that clinically available RNA vaccines may act as potent immune modulators.

Anyone doing science (medical or otherwise) in California, please take a look and consider signing on to this petition to encourage the state to create its own funding institute! https://t.co/XnnHO2SJfs

👉see @DrJJZhang lead a panel on treatments for #NMIBC 🔥Great summaries @auawest #WSAUA25 @urotoday @AmerUrological @UroOnc @VMUrology

Thank you to @AACR for their support of translational bladder cancer research @UCSFUrology. In a bleak federal funding landscape, impactful science will be driven by foundations and philanthropy. Looking forward to sharing what we discover soon. @jonchou05 @SimaPorten

https://t.co/66c7cCYXbY Congrats to @AdityaBagrodia for this amazing achievement @UCSDHealth @UCSanDiego @UCSD_Urology

Dominating the urothelial/testis ca sessions #wsaua25: @UCSFUrology recent alums @domesypantsx3 @MeeraChappidi w/the 1st and 2nd place awards! 🏅

📉 Transperineal prostate biopsy has a <1% infection risk, significantly lower than transrectal. New evidence suggests antibiotic prophylaxis may not be needed in many transperineal cases. A step forward for antimicrobial stewardship. #EAUGuidelines #ProstateCancer #UroUTI

African American men face a higher risk of diagnosis and death from #prostatecancer. @FranklinHuang joins #PCFRetreat25 to share new insights on genetic factors in Black men with high-risk disease—part of a complex mix of factors that contribute to disparities.

Honoring the legacy of Dr. Felix Feng, a visionary leader whose work transformed how we understand and treat #prostatecancer. Dr. Daniel Spratt reflects on his groundbreaking research in genomics and prostate cancer biology.